Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H23N7O3S |
Molecular Weight | 453.517 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C1=CC2=NN(C)C(CO)=C2C=C1)C3=CC=NC(NC4=CC=C(C)C(=C4)S(N)(=O)=O)=N3
InChI
InChIKey=KRXYEFGZHAJXHW-UHFFFAOYSA-N
InChI=1S/C21H23N7O3S/c1-13-4-5-14(10-19(13)32(22,30)31)24-21-23-9-8-20(25-21)27(2)15-6-7-16-17(11-15)26-28(3)18(16)12-29/h4-11,29H,12H2,1-3H3,(H2,22,30,31)(H,23,24,25)
Molecular Formula | C21H23N7O3S |
Molecular Weight | 453.517 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:13:03 GMT 2023
by
admin
on
Sat Dec 16 09:13:03 GMT 2023
|
Record UNII |
SX3LHF7K66
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
72942037
Created by
admin on Sat Dec 16 09:13:03 GMT 2023 , Edited by admin on Sat Dec 16 09:13:03 GMT 2023
|
PRIMARY | |||
|
1414375-49-7
Created by
admin on Sat Dec 16 09:13:03 GMT 2023 , Edited by admin on Sat Dec 16 09:13:03 GMT 2023
|
PRIMARY | |||
|
SX3LHF7K66
Created by
admin on Sat Dec 16 09:13:03 GMT 2023 , Edited by admin on Sat Dec 16 09:13:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE INACTIVE |
Four pazopanib metabolites (GSK1268992, GSK1268997, GSK1071306, and GW700201) have been identified. Only one of these metabolites (GSK1268997) has been shown to inhibit the proliferation of VEGF-stimulated human umbilical vein endothelial cells with potency similar to pazopanib. The other metabolites show at least 10- to 20-fold less activity than the parent compound in the same cellular assay.
|